These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37941480)

  • 1. Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma.
    De Coninck S; De Smedt R; Lintermans B; Reunes L; Kosasih HJ; Reekmans A; Brown LM; Van Roy N; Palhais B; Roels J; Van der Linden M; Van Dorpe J; Ntziachristos P; Van Delft FW; Mansour MR; Pieters T; Lammens T; De Moerloose B; De Bock CE; Goossens S; Van Vlierberghe P
    Haematologica; 2024 May; 109(5):1373-1384. PubMed ID: 37941480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel
    Zabriskie MS; Antelope O; Verma AR; Draper LR; Eide CA; Pomicter AD; Tran TH; Druker BJ; Tyner JW; Miles RR; Graham JM; Hwang JY; Varley KE; Toydemir RM; Deininger MW; Raetz EA; O'Hare T
    Haematologica; 2018 Feb; 103(2):e87-e91. PubMed ID: 29284681
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
    De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
    Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.
    Ishibashi T; Yaguchi A; Terada K; Ueno-Yokohata H; Tomita O; Iijima K; Kobayashi K; Okita H; Fujimura J; Ohki K; Shimizu T; Kiyokawa N
    Exp Hematol; 2016 Mar; 44(3):177-88.e5. PubMed ID: 26703895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.
    Zhang G; Zhang Y; Wu J; Chen Y; Ma Z
    Am J Case Rep; 2017 Nov; 18():1204-1208. PubMed ID: 29133777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
    Schwab C; Ryan SL; Chilton L; Elliott A; Murray J; Richardson S; Wragg C; Moppett J; Cummins M; Tunstall O; Parker CA; Saha V; Goulden N; Vora A; Moorman AV; Harrison CJ
    Blood; 2016 May; 127(18):2214-8. PubMed ID: 26872634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia.
    Heilmann AM; Schrock AB; He J; Nahas M; Curran K; Shukla N; Cramer S; Draper L; Verma A; Erlich R; Ross J; Stephens P; Miller VA; Ali SM; Verglio JA; Tallman MS; Mughal TI
    Leukemia; 2017 Sep; 31(9):1989-1992. PubMed ID: 28552906
    [No Abstract]   [Full Text] [Related]  

  • 8. The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL.
    Xu GF; Zeng Z; Zhang ZB; Zhang XM; Wang M; Xiao Q; Li J; Xie XQ; He S; Fu HH; Liu Y; Yang ZL; Chen Y; Shi J; Wang B; Qiu HY; Zhou Q; Liu Y; Chen SN
    J Cell Mol Med; 2024 Feb; 28(3):e18114. PubMed ID: 38323741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
    Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A
    Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.
    Welsh SJ; Churchman ML; Togni M; Mullighan CG; Hagman J
    Leukemia; 2018 Jan; 32(1):38-48. PubMed ID: 28555080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
    Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
    Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel subclonal rearrangement of the STRN3::PDGFRB gene in de novo acute myeloid leukemia with NPM1 mutation and its leukemogenic effects.
    Wang Z; Liu T; Liu W; Gao X; Wan L; Qiu S; Song Y; Gu R; Tian Z; Wang M; Wang J; Mi Y; Wei S
    Cancer Gene Ther; 2023 Nov; 30(11):1471-1484. PubMed ID: 37550570
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Zhang Y; Gao Y; Zhang H; Zhang J; He F; Hnízda A; Qian M; Liu X; Gocho Y; Pui CH; Cheng T; Wang Q; Yang JJ; Zhu X; Liu X
    Blood; 2018 May; 131(20):2256-2261. PubMed ID: 29434033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
    Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
    Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.
    Lengline E; Beldjord K; Dombret H; Soulier J; Boissel N; Clappier E
    Haematologica; 2013 Nov; 98(11):e146-8. PubMed ID: 24186319
    [No Abstract]   [Full Text] [Related]  

  • 16. IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.
    González-García S; Mosquera M; Fuentes P; Palumbo T; Escudero A; Pérez-Martínez A; Ramírez M; Corcoran AE; Toribio ML
    Blood; 2019 Dec; 134(24):2171-2182. PubMed ID: 31530562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid/Lymphoid Neoplasms Associated With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, or FGFR1 or With PCM1-JAK2.
    Pozdnyakova O; Orazi A; Kelemen K; King R; Reichard KK; Craig FE; Quintanilla-Martinez L; Rimsza L; George TI; Horny HP; Wang SA
    Am J Clin Pathol; 2021 Feb; 155(2):160-178. PubMed ID: 33367495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children.
    Kobayashi K; Mitsui K; Ichikawa H; Nakabayashi K; Matsuoka M; Kojima Y; Takahashi H; Iijima K; Ootsubo K; Oboki K; Okita H; Yasuda K; Sakamoto H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Ohara A
    Br J Haematol; 2014 Jun; 165(6):836-41. PubMed ID: 24628626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FIP1L1-PDGFRA fusion gene in T-lymphoblastic lymphoma: A case report.
    Ali S; Al-Qattan Y; Awny W; Hamadah A; Pinto K; AlShemmari S
    Cancer Rep (Hoboken); 2023 Jan; 6(1):e1769. PubMed ID: 36517458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
    Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP
    PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.